

March 28 - April 1, 2023 | Gothenburg, Sweden • HYBRID





KEY:	Please note the program takes place in CET - Central European Time Gothenburg (Sweden)					
PRE CONFERENCE SYMPOSIUM	SPONSORED SYMPOSIUM	SYMPOSIUM	PLENARY LECTURE	FORUM	OTHER EVENT	
Please note that On-Demand Sessions are	listed at the end of this program.					
		Tuesday, March 28, 2023	3			
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite -Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	
08:00 - 15:50			PRE CONFERENCE SYMPOSIUM : The NTK Fair (09:00 - 13:00)	PRE CONFERENCE SYMPOSIUM - COMMON FEATURES OF NEURODEGENERATIVE DISEASES: EXPLORING THE BRAIN/EYE CONNECTION AND BEYOND : USE IT OR LOSE IT: HOW TINY CHANGES IN ENERGY, METABOLISM AND MITOCHONDRIA CAN LEAD TO NEURODEGENERATIVE DISEASE (08:00 - 15:50)		
17:00 -18:05	OPENING CEREMONY AND AWARDS					
18:05 -18:10	BREAK					
18:10 - 19:20	PLENARY LECTURE 1, 2 and 3					
		WELCOME RECEPTION IN EXHIBITION	(Hosted by The City of Gothenburg and Reg	gion Västra Götaland)		



March 28 - April 1, 2023 | Gothenburg, Sweden + HYBRID



	Wednesday, March 29, 2023					
	On-Demand Oral					
07:00 - 08:30	On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite -Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)
08:30 - 09:00	PLENARY LECTURE 4					
09:00 - 09:10			BREAK			
09:10 - 11:10	BLOOD-BASED BIOMARKERS: SUPPORTING THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE	CELLULAR MECHANISMS OF VULNERABILITY AND ABETA TOXICITY	GENETICS OF NEURODEGENERATION 1	APOE: MECHANISMS AND TREATMENT STRATEGIES	BIOMARKER MODULATORS: KIDNEY FUNCTION, ETHNICITY, AND GENDER	αSYNUCLEIN, PATHOPHYSIOLOGY: AGGREGATION AND SEEDING
11:10 - 11:40		EXHIBITION, POSTERS AND COFFEE BREAK				
11:40 - 13:25	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
13:25 - 14:45		EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS				
14:45 - 16:45	FORUM 1: BLOOD-BASED BIOMARKERS COMPARISON TO CSF AND IMAGING BIOMARKERS. ASSESSMENT FOR DIAGNOSES & TREATMENT EFFECTS: HOW TO MEASURE MINIMAL CLINICAL EFFICACY? (14:45 - 15:45)  FORUM 2: IMMUNOTHERAPIES IN AD: FROM	MICROGLIA. TREM2, NEUROINFLAMMATION 1	AD THERAPY: TARGETING TAU	TRANSLATIONAL DRUG DISCOVERY: THE VALUE OF ANIMAL MODELS AND ORGANOIDS	TARGETING NI RP3 AND	GENETICS OF NEURODEGENERATION 2
	BASICS TO APPROVAL (15:55 - 16:55)					
16:50 - 17:20		EXHIBITION, POSTERS AND COFFEE BREAK				
17:20 - 19:20	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	FLUID BIOMARKERS AND IMAGING IN PD AND LBD	TDP43-, PROGRANULIN-, AND C9ORF72- RELATED DISEASES	CELL REPLACEMENT THERAPY: IPSC, GLIA AND GRAFTS	GLIAL CELLS AND MECHANISMS OF NEURODEGENERATION	SELECTIVE VULNERABILITY, GLIAL CELLS AND MECHANISMS OF NEURODEGENERATION





March 28 - April 1, 2023 | Gothenburg, Sweden HYBRID

		Thurso	day, March 30, 2023			
	On-Demand Oral					
07:00 - 08:30	On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite -Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtua Platform)
08:00 - 08:30	PLENARY LECTURE 5					
08:30 - 08:40			BREAK			
08:40 - 10:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	CEREBRAL CONSEQUENCES OF VASCULAR CHANGES	ALPHA-SYNUCLEIN PATHOGENESIS, DETECTION & TREATMENT STRATEGIES	LIPID DYSHOMEOSTASIS IN NEUROGENERATIVE DISEASES	SYNAPTIC HOMEOSTASIS AND DYSFUNCTION, NEURONAL NETWORKS	TDP43- AND C9ORF72-RELATED DISEASES
10:40- 11:10			EXHIBITION, POSTERS AND	COFFEE BREAK		
11:10-12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50- 13:50			EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS			
13:50-15:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (13:50 - 14:50)	ABETA TARGETING THERAPIES IN AD 1	MRI 1	FTD, ALS: TDP-43 , C9ORF72 AND TMEM106B	MITOCHONDRIA, AUTOPHAGY, MITOPHAGY IN AD, PD	FLUID BIOMARKERS 1
15:50-16:20			EXHIBITION, POSTERS AND	COFFEE BREAK	1	•
16:20 - 18:20	FORUM 3: PHASE HII IN AD: DRUG DEVELOPMENT AND RELEVANCE FOR HETEROGENEITY OF THE DISEASE (16:20-17:20)  FORUM 4: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, GBA PATHOLOGIES (17:25 - 18:25)	DEMENTIA PREVENTION STRATEGIES; VALIDATING BIOMARKERS	APOE MECHANISMS AND TREATMENT STRATEGIES	FTD, ALS: C9ORF72, TDP-43	EXOSOMES	TAU PATHOLOGY 1
18:25 -18:35			BREAK			•
18:35 - 19:35	AD DRUG DEVELOPMENT CLINICAL TRIALS	ABETA & TAU TARGETING THERAPIES	PLASMA BIOMARKERS	FLUID BIOMARKERS, IMAGING	ASTROGLIA	TAU PATHOLOGY 2



March 28 - April 1, 2023 | Gothenburg, Sweden HYBRID



		Frid	ay, March 31, 2023			
	On-Demand Oral					
07:00 - 08:30	6 On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite -Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)
08:00 - 08:30	PLENARY LECTURE 6					
08:30 - 08:40			BREAK			
08:40 - 10:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (08:55 - 10:40)	HETEROGENEITY AND SIMILARITIES IN THE NEUROPATHOLOGIES OF LBD, PD, FAD, DOWN SYNDROME AND AD	MICROGLIA. TREM2, NEUROINFLAMMATION 2	CHOLINERGIC MECHANISMS IN AD AND PD	BRAIN GUT INTERACTIONS MICROBIOME 1	EXPLORING NEW TARGETS IN AD, FTD, PD AND LBD
10:40 - 11:10			EXHIBITION, POSTERS AND	COFFEE BREAK		
11:10 - 12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50 - 13:50		EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS				
13:50 - 15:50	ABETA TARGETING THERAPIES IN AD 1	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	FLUID BIOMARKERS AND IMAGING IN MCI,	NEUROPATHOLOGIES OF LBD, PD, ALS, FAD, AND AD	TAU AND SYNUCLEIN TOXICITIES AND CELLULAR INTERACTIONS	ANIMAL MODELS, ORGANOIDS, SINGLE CELLS, IMAGING
15:50 - 16:20			EXHIBITION, POSTERS AND	COFFEE BREAK	•	•
16:20 - 18:30	FORUM 5: ANTI-TAU THERAPIES IN CLINICAL TRIALS (16:20 - 17:20)	CLINICAL TRIAL DESIGNS	SEX, GENDER, SIMILARITIES AND DIFFERENCES IN BIOMARKERS & PATHOPHYSIOLOGY	BLOOD BIOMARKERS	ALPHA-SYNUCLEIN, PD MECHANISTIC ASPECTS	SELECTIVE VULNERABILITY, PATHOPHYSIOLOGY, PATHOGENESIS IN AD, PD
						_
18:30 - 18:40	BREAK					
18:40 - 19:40	NEUROPATHOLOGIES OF LBD, PD, ALS, FAD, AND AD	TAU AND SYNUCLEIN TOXICITIES AND CELLULAR INTERACTIONS	FLUID BIOMARKERS AND IMAGING IN MCI,	ANIMAL MODELS, ORGANOIDS, SINGLE CELLS, STEM CELLS, IMAGING	EEG AND OTHER ASSESSMENT TOOLS	SELECTIVE VULNERABILITY, PATHOPHYSIOLOGY, PATHOGENESIS IN AD, PD 2



AD/PD 2023
March 28 - April
GOTHENBURG

March 28 - April 1, 2023 | Gothenburg, Sweden • HYBRID

	Saturday, April 1, 2023						
	On-Demand Oral						
07:00 - 08:30	6 On-demand symposia						
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite -Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)	
08:00 - 08:30	PLENARY LECTURE 7						
08:30 - 08:40			BREAK				
08:40 - 10:40	HOW SHOULD WE USE FLUID AND IMAGING BIOMARKERS IN CLINICAL PRACTICE?	AD & FAD THERAPEUTIC STRATEGIES	THE VULNERABLE BRAIN AND DEGENERATIVE MECHANISMS IN AD, PD AND TRAUMATIC BRAIN INJURY	PET 1	TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS IN AD, PD AND LBD DRUG DEVELOPMENT	GENETICS OF NEURODEGENERATION 3	
10:40 - 11:10		EXHIBITION, POSTERS AND COFFEE BREAK					
11:10 -13:10	TAUPATHIES: PATHOGENIC MECHANISMS	FLUID BIOMARKERS 2	EXPLORING NEW TARGETS IN AD, PD AND LBD	PET 2	THE POTENTIAL ROLE OF ASTROCYTES, MICROGLIA IN NEURODEGENATION	α-SYNUCLEINOPATHIES: DISEASE MECHANISMS, PATHOPHYSIOLOGY: MODELING OF DISEASE PROGRESSION	
13:10 - 14:45			EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS				
14:45 - 16:45	FORUM 6: DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARDS APPROVAL (14:45 - 15:45)	ADVANCES IN PD AND LBD DIAGNOSIS AND DRUG DEVELOPMENT	COVID-19 IMPACT ON NEURODEGENERATIVE DISEASES	FLUID BIOMARKERS AND IMAGING IN AD, PD AND PSP	TREM2, MICROGLIA, ASTROCYTES	EEG, SLEEP AND OTHER ASSESSMENT TOOLS	
16:55 - 17:25		EXHIBITION, POSTERS AND COFFEE BREAK					
17:25 - 19:25	DIAGNOSTIC ACCURANCY, IMAGING AND FLUID BIOMARKERS AND IMAGING IN AD, FTD, PD, LBD	BACE-1, PRESENILIN, GAMMA-SECRETASE, TACE, APP, Abeta TRUNCATION, TOXICITY	SOC DRUGS AND OTHER TARGETED THERAPIES IN AD (CLNICAL TRIALS)	DRUG DEVELOPMENT IN AD, PD, LBD	AD, PD, LBD, BIOMARKERS, DIAGNOSIS, IMAGING & CLINICAL TRIALS	PSYCHIATRIC MANIFESTATIONS AND CORRELATES IN AD, PD AND LBD	
19:25 - 19:35	CLOSING CEREMONY		•		•		

Wednesday, March 29, 2023
GENETICS OF NEURODEGENERATION 4
GENETICS OF NEURODEGENERATION 5
GENETICS OF NEURODEGENERATION 5
VULNERABILITY AND RISK FACTORS, PROGRESSION
NEURODEGENERATION AND PATHOLOGY
VULNERABILITY AND RISK FACTORS, HETEROGENE
PROGRESSION NEURODEGENERATION AND PATHO
DIGITAL AND CLOUD BASED TOOLS, AI, MACHIN
LEARNING
NLRP3 INFLAMMASOME, NEUROINFLAMMATION, T
MICROGLIA DYSFUNCTION
DIGITAL HEALTH TECHNOLOGIES, MACHINE LEAR
DIGITAL HEALTH TECHNOLOGIES, MACHINE LEAR
Thursday, March 30, 2023
TAU PATHOLOGY
FLUID BIOMARKERS AND IMAGING IN AD, PD AND
FLUID BIOMARKERS 3
FLUID BIOMARKERS 4
PET 3  MCI, AD & FAD THERAPEUTIC STRATEGIES
MICI, AD & FAD THERAPEUTIC STRATEGIES
BACE-1, BACE-2, PRESENILIN, GAMMA-SECRETASE,
APP
CEREBRAL CONSEQUENCES OF VASCULAR CHANGE
Friday, March 31, 2023
α-SYNUCLEINOPATHIES: ALPHA-SYNUCLEIN
PATHOGENESIS, DOPAMINE, LRRK2, PATHOPHYSIO
α-SYNUCLEINOPATHIES: ALPHA-SYNUCLEIN PATHOGENESIS, DOPAMINE, ANIMAL MODELS
ORGANOIDS
THERAPEUTIC TARGETS IN PD AND LBD: PRECLINICA
CLINICAL DRUG DEVELOPMENT
MITOCHONDRIAL DYSFUNCTION, AUTOPHAGY
MITOPHAGY IN AD, PD
BRAIN GUT INTERACTIONS – MICROBIOME 2
AD, MCI, PD: PSYCHIATRIC & NEUROPHSYOLOGIC MANIFESTATIONS. ECONOMIC STATUS, CARE & SUF
WANTESTATIONS. ECONOMIC STATUS, CARE & SUF
A-BETA TOXICITY
THERAPEUTIC TARGETS IN AD: PRECLINICAL STUD
Saturday , April 1, 2023
TDP43- AND C9ORF72-RELATED DISEASES

### DISEASE MECHANISMS, PATHOPHYSIOLOGY: ASTROCYTES, MICROGLIA, IMMUNE PROTECTION, NEUROINFLAMMATION

CLINICAL TRIALS DESIGN, DIAGNOSTIC CRITERIA

CLINICAL AND NEUROPATHOLOGICAL FEATURES ACROSS
MULTIPLE NEURODEGENERATIVE DISEASES

IPSC, STEM CELLS, CELL REPLACEMENT THERAPY

MRI 2

A-BETA & TAU TARGETING THERAPIES IN AD AND DISEASE-MODIYFING THERAPIES

ANIMAL MODELS FOR AD